(NASDAQ: GH) Guardant Health's forecast annual revenue growth rate of 25.97% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 6.54%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.17%.
Guardant Health's revenue in 2026 is $1,278,884,000.On average, 32 Wall Street analysts forecast GH's revenue for 2026 to be $190,076,794,875, with the lowest GH revenue forecast at $178,712,772,975, and the highest GH revenue forecast at $195,082,375,950. On average, 32 Wall Street analysts forecast GH's revenue for 2027 to be $256,366,922,625, with the lowest GH revenue forecast at $231,339,017,250, and the highest GH revenue forecast at $287,753,268,825.
In 2028, GH is forecast to generate $351,337,677,075 in revenue, with the lowest revenue forecast at $289,241,414,550 and the highest revenue forecast at $462,001,604,625.